RNS Number : 5821H
N4 Pharma PLC
25 March 2020

25 March 2020

N4 Pharma plc
("**N4 Pharma**", the "**Company**" or the "**Group**")

Changes to AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces an update on the Company's upcoming Annual General Meeting ("AGM").

In light of the most recent advice from the Government to the general public in response to the COVID-19 pandemic, it is clear that the Company will not be able to proceed with the AGM on the date and time anticipated. The Company has therefore decided to withdraw the AGM notice for the meeting originally convened for 31 March 2020 and issue a new AGM notice for a meeting to be held at 10:00 a.m. on 23 April 2020 at the Company's offices at Weston House, Bradgate Park View, Chellaston, Derby DE73 5U. The new notice of AGM and proxy form will be sent to Shareholders in respect of the reconvened AGM and copies will shortly be available from the Company Reports section of the Company's website, www.n4pharma.com.

The Company advises that only the formal business set out in the notice of meeting will be considered at the AGM. The Company will arrange for a separate presentation to Shareholders and Q&A to be arranged via a webinar or video conference, the details of which will be announced in due course. The Company is taking these precautionary measures to safeguard Shareholders' health and to make the AGM as safe and efficient as possible.

It is anticipated that the formal AGM to consider and vote upon the various resolutions set out in the notice of meeting would be attended only by two officers of the Company and all other officers and advisers would not be in attendance. Shareholders are discouraged from attending the AGM in person given the current Government advice. Shareholders wishing to vote on any of the matters of business are instead urged to do so via a completion of a proxy form which can be completed and submitted to the Company. Proxy votes already submitted in respect of the original AGM date will not be valid at the reconvened AGM.

Proxies should be completed and returned in accordance with the instructions on the form of proxy and the latest time for lodging proxies is 10:00 a.m. on 21 April 2020. The completion and return of a form of proxy will not preclude a member from attending in person at the meeting and voting should the member wish to do so. In order that any proxy votes of those members who choose to not attend and vote in person are fully reflected in the voting on the resolutions, the Chairman will direct that voting on all resolutions set out in the notice of meeting will take place by way of a poll. Under the Company's Articles, votes on a poll may be given personally, by a corporate representative or by Proxy. Every Shareholder who is present in person or by a corporate representative or by Proxy shall have one vote for each share held by them.

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR

Allenby Capital Limited — Tel: +44(0)203 328 5656
James Reeve/Asha Chotai

Scott PR Tel: +44(0)1477 539 539
Georgia Smith

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCMZGZFFKKGGZM